PROCEPT BioRobotics Reports Fourth Quarter and Full Year 2023 Results SAN JOSE, Calif., February 27, 2024 -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported financial results for the year ended December 31, 2023. Recent Highlights "I am extremely proud of our commercial achievements in 2023," said Reza Zadno, Chief Executive Officer. "We succeeded in elevating the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40797 PROCEPT BioRobotics Corporation (Exact name of registrant as specified in its charter) Indicate by check mark whether ...

7 U.S. men actively MANAGED for BPH 12M All numbers are approximate. Vuichoud, C, Loughlin, K. Benign prostatic hyperplasia: epidemiology, economics and evaluation. Can J Urol. 2015 Oct;22 Suppl 1:1-6. Data on File, PROCEPT BioRobotics Total surgeries based on 2019 market data, representing pre-pandemic surgeries PHARMACEUTICAL FALLOUT C o p y r i g h t 2 0 2 3 P R O C E P T B i o R o b o t i c s C o r p o r a t i o n . A l l R i g h t s R e s e r v e d . REAL-TIME, MULTI-DIMENSIONAL VISUALIZATION OF THE EN ...

Financial Data and Key Metrics Changes - Total revenue for Q3 2023 was $35.1 million, representing a growth of 72% compared to Q3 2022 [7][38] - U.S. revenue for the quarter was $32.3 million, reflecting a growth of 73% year-over-year [38] - Net loss for Q3 2023 was $24.6 million, compared to a net loss of $22.6 million in the same period of the prior year [42] - Adjusted EBITDA loss was $19.4 million, compared to a loss of $18.3 million in Q3 2022 [42] - Cash and cash equivalents as of September 30, 2023, were approximately $287 million, including $162 million raised from an equity offering [42][36] Business Line Data and Key Metrics Changes - Sold 38 robots in the U.S. during Q3 2023, representing a unit growth of 46% compared to the prior year [8] - U.S. handpiece and consumable revenue increased by 113% compared to Q3 2022, amounting to $17 million [9][18] - Monthly utilization per account was 6.4 handpieces, which increased sequentially by 5% compared to Q2 2023 [10][39] - U.S. install base grew by 62% compared to the end of 2022, reaching 271 systems by the end of Q3 2023 [30][40] Market Data and Key Metrics Changes - International revenue for Q3 was $2.8 million, representing a growth of 62% [41] - The company expects full-year international revenue to be approximately $11.5 million [22] - In the UK, NICE granted a strong endorsement for Aquablation therapy, which is expected to enhance market penetration [13] Company Strategy and Development Direction - The company plans to invest in expanding its sales infrastructure in the UK to accelerate growth [35] - The strategy focuses on long-term clinical data, gaining reimbursement coverage, and building a high-performing sales team [28] - The company aims to become the standard of care for treating men with BPH, with Aquablation therapy currently representing only 6% of annual receptive BPH procedures in the U.S. [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving long-term growth plans, citing positive trends in all tracked metrics [16] - The company is not providing 2024 financial guidance but remains optimistic about growth drivers such as increased utilization and a robust capital sales pipeline [50][51] - Management noted that the addition of UnitedHealthcare coverage allows access to approximately 95% of men in the U.S. [37] Other Important Information - The company completed an equity follow-on offering in August 2023, raising $162 million to strengthen its balance sheet [15] - The company moved its corporate headquarters to a larger facility in San Jose to support future growth [36] Q&A Session Summary Question: How are new systems performing in terms of utilization? - Management noted that new accounts typically launch with two to three surgeons, contributing to increased utilization [46][65] Question: What are the key drivers for revenue growth in 2024? - Management highlighted strong pipeline growth, increased utilization, and the addition of UnitedHealthcare as key drivers for future growth [50][51] Question: How does the company view the competitive landscape regarding TURP and Greenlight procedures? - Management indicated that TURP and Greenlight are the primary competitors, with Aquablation therapy offering advantages such as shorter therapy time and faster recovery [76] Question: What is the expected impact of IDN relationships on pricing? - Management stated that IDN relationships do not negatively impact system average selling prices and that they are on track to have most large IDNs under contract by the end of 2023 [79] Question: Can you provide insights on the Aquablation therapy for prostate cancer? - Management expressed excitement about the potential of Aquablation therapy for prostate cancer, emphasizing that it is still early in the research phase [126][127]

Financial Data and Key Metrics Changes - Total revenue for Q2 2023 was $33.1 million, representing growth of 98% compared to Q2 2022 [140] - U.S. revenue for the quarter was $29.9 million, representing growth of 102% compared to the prior year period [145] - Net loss was $25.3 million for Q2 2023 compared to $19.2 million in the same period of the prior year [32] - Adjusted EBITDA was a loss of $19.9 million compared to a loss of $14.6 million in Q2 2022 [32] - Gross margin for Q2 2023 was a record 56%, with full year 2023 gross margins expected to be approximately 55% [30][26] Business Line Data and Key Metrics Changes - Sold a record 40 robotic systems in the U.S., generating total U.S. system revenue of $14.8 million, representing growth of 74% compared to the prior year [5][9] - U.S. handpiece and consumable revenue increased 138% compared to Q2 2022, with 3,904 handpieces shipped in Q2 2023, representing unit growth of 124% [29][41] - Average selling price for systems was $370,000, up 5% compared to Q1 2023 [10] Market Data and Key Metrics Changes - International revenue for Q2 was $3.2 million, representing growth of 68% compared to the prior year period, driven primarily by strong performance in the U.K. [30][144] - Approximately 95% of men in the U.S. now have access to Aquablation therapy following UnitedHealthcare's updated coverage policy [7] Company Strategy and Development Direction - The company plans to invest further in the U.K. market to accelerate growth and expand patient awareness [8] - The company continues to expect approximately 55% of system sales to be in the second half of 2023, equating to 144 placements for the full year [23] - The company signed a national sales contract with the largest IDN in the U.S., which will secure pricing for system placements and handpieces sold [136] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in meeting sales expectations due to a growing capital sales pipeline and high surgeon retention rates [5][6] - Management noted that while Q3 system sales are expected to be down relative to Q2, Q4 is anticipated to be the strongest quarter of the year [23] - Management highlighted that the increase in operating expenses is associated with strategic investments in R&D and commercial team expansion [26] Other Important Information - The company expects full year 2023 total revenue guidance to be $131 million, representing growth of 75% compared to 2022 [33] - The company anticipates a modest benefit from UnitedHealthcare's coverage in Q4, contributing to expanded utilization [148] Q&A Session All Questions and Answers Question: Can you provide insights on patient demand for Aquablation treatment? - Management noted that there is an increase in patient demand, with patients actively seeking Aquablation treatment and awareness growing through online activities [40][52] Question: What are the plans for capital rep sales force expansion in 2023? - Management indicated that the capital sales team has been expanded from 20 to 30 reps, with plans to continue adding more reps to ensure continuity and support for growth [55] Question: How do you expect the impact of UnitedHealthcare's coverage to manifest? - Management does not anticipate a significant impact in Q3 but expects a modest benefit in Q4 from the coverage expansion [148][86] Question: Can you comment on the capital environment and system placements? - Management observed that hospitals are prioritizing spending on innovative treatments, which aligns with the company's offerings [112] Question: What is the typical time frame to close on a system placement? - Management stated that the typical time frame to close on a system placement ranges from 3 to 9 months, depending on various factors [122]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40797 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition peri ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40797 PROCEPT BioRobotics Corporation (Exact name of registrant as specified in its charter) | Delaware | | | 26-0199180 | | --- | --- | -- ...

Start Time: 08:00 January 1, 0000 8:56 AM ET PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Q1 2023 Earnings Conference Call April 27, 2023, 08:00 AM ET Company Participants Reza Zadno - President and CEO Kevin Waters - EVP and CFO Matt Bacso - VP, IR and Business Operations Conference Call Participants Craig Bijou - Bank of America Joshua Jennings - Cowen Ryan Zimmerman - BTIG Chris Pasquale - Nephron Research Neil Chatterji - B. Riley Richard Newitter - Truist Nathan Treybeck - Wells Fargo Matthew Mishan - ...

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Q4 2022 Results Conference Call February 28, 2023 4:30 PM ET Company Participants Matt Bacso - Vice President-Investor Relations Reza Zadno - Chief Executive Officer Kevin Waters - Senior Vice President and Chief Financial Office Conference Call Participants Joshua Jennings - Cowen Craig Bijou - Bank of America Chris Pasquale - Nephron Richard Newitter - Truist Neil Chatterji - B. Riley Nathan Treybeck - Wells Fargo Matthew Mishan - KeyBanc Ryan Zimmerman - BTIG ...

Part I [Business](index=6&type=section&id=Item%201.%20Business) PROCEPT BioRobotics is a surgical robotics company treating BPH with its AquaBeam Robotic System, generating revenue from system sales and handpieces - The company develops, manufactures, and sells the AquaBeam Robotic System, an image-guided surgical robot for treating benign prostatic hyperplasia (BPH) using its proprietary Aquablation therapy[19](index=19&type=chunk) - As of December 31, 2022, the company had an installed base of **243 AquaBeam Robotic Systems globally**, with 167 located in the United States[19](index=19&type=chunk) Key Financials (FY 2021-2022) | Metric | 2022 ($M) | 2021 ($M) | | :--- | :--- | :--- | | **Revenue** | $75.0 | $34.5 | | **Net Loss** | $87.2 | $59.9 | | **Accumulated Deficit** | $348.7 | - | - The company estimates its total addressable market opportunity in the United States to be in excess of **$20 billion**, targeting approximately **8.2 million patients**[22](index=22&type=chunk)[38](index=38&type=chunk) [Growth Strategies](index=9&type=section&id=Our%20Growth%20Strategies) The company aims to grow its installed base, increase system utilization, broaden payor coverage, invest in R&D, and expand internationally - Grow the installed base of AquaBeam Robotic Systems by targeting **860 high-volume U.S. hospitals** that account for approximately **70% of resective BPH procedures**[33](index=33&type=chunk) - Increase system utilization by converting medium-to-high volume resective cases to Aquablation therapy and expanding into the larger BPH patient population currently on or having failed drug therapy[34](index=34&type=chunk) - Continue to broaden private payor coverage, leveraging existing positive Medicare coverage decisions which cover **100% of eligible patients**[35](index=35&type=chunk) - Invest in R&D to drive continuous improvements, including integrating AI and machine-learning for enhanced treatment planning, and potentially expanding into new urologic conditions[35](index=35&type=chunk) - Further penetrate and expand into international markets such as Germany, France, the UK, Korea, and Japan[35](index=35&type=chunk)[36](index=36&type=chunk) [Market Overview](index=11&type=section&id=Market%20Overview) The BPH market is significant, with current surgical interventions often requiring a compromise between efficacy and safety - BPH impacts an estimated **40 million men in the U.S.**, with **12 million managed by a physician**, and an addressable patient population including **6.7 million on drug therapy**[38](index=38&type=chunk) - Alternative surgical interventions for BPH often require a compromise between efficacy and safety, with resective procedures offering durable relief but high complication rates, and non-resective procedures having better safety but less significant relief[53](index=53&type=chunk)[54](index=54&type=chunk)[55](index=55&type=chunk) [Our Solution](index=14&type=section&id=Our%20Solution) The AquaBeam Robotic System offers an image-guided, heat-free Aquablation therapy for BPH, providing significant relief with a favorable safety profile - The AquaBeam Robotic System delivers Aquablation therapy, the first and only image-guided robotic therapy for BPH, combining real-time imaging, personalized planning, automated robotics, and heat-free waterjet resection[56](index=56&type=chunk)[58](index=58&type=chunk) - Key benefits of Aquablation therapy include significant and durable symptom relief, a favorable safety profile with low rates of irreversible complications, and consistent outcomes independent of prostate size, shape, or surgeon experience[63](index=63&type=chunk) - The company's clinical evidence is supported by **nine clinical studies**, including the WATER and WATER II studies, and nearly **150 peer-reviewed publications**[26](index=26&type=chunk)[63](index=63&type=chunk)[64](index=64&type=chunk) [Intellectual Property](index=20&type=section&id=Intellectual%20Property) The company maintains a robust patent portfolio and holds exclusive license agreements for key technologies - As of December 31, 2022, the company's patent portfolio included **135 issued patents** (42 U.S., 93 foreign) and **88 pending patent applications**[33](index=33&type=chunk)[91](index=91&type=chunk) - The company has an exclusive, worldwide, royalty-free license agreement with AquaBeam LLC for patents related to urology and another with HydroCision, Inc. for patents related to fluid jet technology[98](index=98&type=chunk)[100](index=100&type=chunk) [Government Regulation](index=22&type=section&id=Government%20Regulation) The AquaBeam Robotic System is regulated as a Class II medical device in the U.S. and is subject to extensive domestic and international oversight - The AquaBeam Robotic System is regulated as a **Class II medical device** in the U.S. and was initially granted marketing authorization through the FDA's de novo classification pathway[111](index=111&type=chunk)[278](index=278&type=chunk) - The company is subject to extensive ongoing FDA oversight, including Quality System Regulation (QSR), medical device reporting, and regulations on marketing and promotion[119](index=119&type=chunk)[121](index=121&type=chunk) - Internationally, the company must comply with regulations such as the Medical Devices Regulation (MDR) in the European Economic Area (EEA) and has obtained regulatory approvals in Japan and South Korea[130](index=130&type=chunk)[135](index=135&type=chunk)[136](index=136&type=chunk) [Risk Factors](index=32&type=section&id=Item%201A.%20Risk%20Factors) The company faces risks from net losses, core product dependence, market acceptance, supply chain, competition, and regulatory compliance - The company has a history of significant net losses, reporting a loss of **$87.2 million in 2022**, and expects to incur operating losses for the foreseeable future[168](index=168&type=chunk) - Revenue is primarily generated from the AquaBeam Robotic System and its single-use handpieces, making the company highly dependent on the success of these products[170](index=170&type=chunk) - Commercial success depends on market acceptance by hospitals, surgeons, and patients, which is not guaranteed[183](index=183&type=chunk) - The company faces competition from larger, more established companies like Boston Scientific and Teleflex, which have greater financial and marketing resources[198](index=198&type=chunk)[199](index=199&type=chunk) - Reliance on third-party, single-source suppliers for critical components creates vulnerability to supply shortages and price fluctuations[209](index=209&type=chunk) - The business is subject to extensive government regulation, and failure to maintain regulatory approvals or comply with healthcare laws could negatively impact operations[268](index=268&type=chunk)[272](index=272&type=chunk) [Properties](index=81&type=section&id=Item%202.%20Properties) The company leases its principal office in Redwood City and plans to relocate to a new, larger facility in San Jose - The company's principal office is a leased space of **43,485 sq. ft.** in Redwood City, CA, with the lease term extending to January 2024[424](index=424&type=chunk) - A new lease for a **158,221 sq. ft. facility** in San Jose, CA, commenced in July 2022 for a term of 122 months, with plans to relocate headquarters and manufacturing operations[203](index=203&type=chunk)[425](index=425&type=chunk) [Legal Matters](index=81&type=section&id=Item%203.%20Legal%20Matters) The company is not currently involved in any legal proceedings expected to have a material adverse effect on its business - As of the report date, the company is not involved in any legal proceedings that are expected to have a material adverse effect on the business[426](index=426&type=chunk) Part II [Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](index=82&type=section&id=Item%205.%20Market%20for%20Registrant's%20Common%20Equity%2C%20Related%20Stockholder%20Matters%20and%20Issuer%20Purchases%20of%20Equity%20Securities) The company's common stock trades on Nasdaq under 'PRCT' since September 2021, with no cash dividends paid or anticipated - The company's common stock began trading on the Nasdaq Global Select Market under the symbol "**PRCT**" on September 14, 2021[429](index=429&type=chunk) - The company has never declared or paid cash dividends and does not plan to in the foreseeable future, with future earnings intended for reinvestment into the business[431](index=431&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=84&type=section&id=Item%207.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) In 2022, revenue grew 118% to $75.0 million, but increased operating expenses led to a higher net loss, with $221.9 million in cash Financial Performance (2021 vs. 2022) | Metric | 2022 ($M) | 2021 ($M) | Change (%) | | :--- | :--- | :--- | :--- | | **Revenue** | $75.0 | $34.5 | 118% | | **Gross Profit** | $37.1 | $15.9 | 134% | | **Gross Margin** | 49% | 46% | - | | **R&D Expenses** | $29.0 | $19.0 | 53% | | **SG&A Expenses** | $88.8 | $51.0 | 74% | | **Net Loss** | ($87.2) | ($59.9) | 46% | - Revenue growth was driven by a **$17.9 million increase from system sales and rentals** and a **$20.3 million increase from handpieces and consumables**, reflecting higher volumes and average selling prices[460](index=460&type=chunk) - As of December 31, 2022, the company had **$221.9 million in cash and cash equivalents** and **$52.0 million in outstanding long-term debt**[469](index=469&type=chunk) - Net cash used in operating activities increased to **$80.4 million in 2022** from $57.3 million in 2021, primarily due to the higher net loss and investments in operating assets to support growth[478](index=478&type=chunk)[479](index=479&type=chunk)[480](index=480&type=chunk) [Quantitative and Qualitative Disclosures about Market Risk](index=94&type=section&id=Item%207A.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) The company faces market risks from interest rates, credit, and foreign currency, but does not expect a material impact and does not use hedging - The company is exposed to interest rate risk as its outstanding debt bears interest at a variable rate based on SOFR, though a **100 basis point change** is not expected to have a material impact[506](index=506&type=chunk) - Foreign currency risk exists due to sales and expenses denominated in foreign currencies, primarily the Euro, and the company does not currently hedge this exposure[509](index=509&type=chunk)[510](index=510&type=chunk) [Financial Statements and Supplementary Data](index=95&type=section&id=Item%208.%20Financial%20Statements%20and%20Supplementary%20Data) Audited consolidated financial statements for 2022 and 2021, including Balance Sheets, Statements of Operations, and Cash Flows, are presented with notes [Consolidated Balance Sheets](index=98&type=section&id=Consolidated%20Balance%20Sheets) This section presents the company's financial position, detailing assets, liabilities, and equity as of December 31, 2022 and 2021 Consolidated Balance Sheet Data (as of Dec 31) | Metric | 2022 ($M) | 2021 ($M) | | :--- | :--- | :--- | | **Cash and cash equivalents** | $221.9 | $304.3 | | **Inventory** | $28.5 | $13.1 | | **Total Assets** | $309.3 | $337.0 | | **Long-term debt** | $51.2 | $50.0 | | **Total Liabilities** | $112.3 | $69.9 | | **Total Stockholders' Equity** | $197.1 | $267.1 | [Consolidated Statements of Operations and Comprehensive Loss](index=99&type=section&id=Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) This section presents the company's financial performance, detailing revenues, expenses, and net loss for the years ended December 31, 2022 and 2021 Consolidated Statement of Operations (Year Ended Dec 31) | Metric | 2022 ($M) | 2021 ($M) | | :--- | :--- | :--- | | **Revenue** | $75.0 | $34.5 | | **Gross Profit** | $37.1 | $15.9 | | **Loss from operations** | ($80.7) | ($54.2) | | **Net loss** | ($87.2) | ($59.9) | | **Net loss per share** | ($1.96) | ($3.63) | [Consolidated Statements of Cash Flows](index=101&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) This section presents the company's cash flows, detailing inflows and outflows from operating, investing, and financing activities for 2022 and 2021 Consolidated Statement of Cash Flows (Year Ended Dec 31) | Metric | 2022 ($M) | 2021 ($M) | | :--- | :--- | :--- | | **Net cash used in operating activities** | ($80.4) | ($57.3) | | **Net cash used in investing activities** | ($2.7) | ($0.6) | | **Net cash provided by financing activities** | $3.6 | $262.1 | | **Net (decrease) increase in cash** | ($79.4) | $204.2 | [Controls and Procedures](index=121&type=section&id=Item%209A.%20Controls%20and%20Procedures) Management concluded that disclosure controls and internal control over financial reporting were effective as of December 31, 2022, as audited by PwC LLP - Management concluded that the company's disclosure controls and procedures were effective as of December 31, 2022[657](index=657&type=chunk) - Based on the COSO framework, management concluded that the company's internal control over financial reporting was effective as of December 31, 2022, an assessment audited by PricewaterhouseCoopers LLP[518](index=518&type=chunk)[659](index=659&type=chunk) Part III [Directors, Executive Officers and Corporate Governance](index=122&type=section&id=Item%2010.%20Directors%2C%20Executive%20Officers%20and%20Corporate%20Governance) Information on directors, executive officers, and corporate governance is incorporated by reference from the company's 2023 Proxy Statement - Information required by this item is incorporated by reference from the company's 2023 Proxy Statement[664](index=664&type=chunk) [Executive Compensation](index=122&type=section&id=Item%2011.%20Executive%20Compensation) Information on executive compensation is incorporated by reference from the company's 2023 Proxy Statement - Information required by this item is incorporated by reference from the company's 2023 Proxy Statement[665](index=665&type=chunk) [Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters](index=122&type=section&id=Item%2012.%20Security%20Ownership%20of%20Certain%20Beneficial%20Owners%20and%20Management%20and%20Related%20Stockholder%20Matters) Information on security ownership and equity compensation plans is incorporated by reference from the company's 2023 Proxy Statement - Information required by this item is incorporated by reference from the company's 2023 Proxy Statement[665](index=665&type=chunk) [Certain Relationships and Related Transactions, and Director Independence](index=122&type=section&id=Item%2013.%20Certain%20Relationships%20and%20Related%20Transactions%2C%20and%20Director%20Independence) Information on related party transactions and director independence is incorporated by reference from the company's 2023 Proxy Statement - Information required by this item is incorporated by reference from the company's 2023 Proxy Statement[666](index=666&type=chunk) [Principal Accountant Fees and Services](index=122&type=section&id=Item%2014.%20Principal%20Accountant%20Fees%20and%20Services) Information on principal accountant fees and services is incorporated by reference from the company's 2023 Proxy Statement - Information required by this item is incorporated by reference from the company's 2023 Proxy Statement[666](index=666&type=chunk) Part IV [Exhibits, Financial Statement Schedules](index=123&type=section&id=Item%2015.%20Exhibits%2C%20Financial%20Statement%20Schedules) This section lists all exhibits filed with the Form 10-K, including corporate governance documents, material contracts, and required certifications - This section lists all exhibits filed with the Form 10-K, including corporate governance documents, material contracts such as lease and loan agreements, and required certifications[669](index=669&type=chunk)[670](index=670&type=chunk)